Close

Daclatasvir MAA for Hepatitis C Validated for Accelerated Regulatory Review by the EMA (BMY)

January 8, 2014 7:21 AM EST Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated the company's marketing authorization application ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login